Skip to main content
SpringerLink
Log in

Dermatofiller

Ein aktueller Überblick

Fillers

An overview

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Nachfrage nach minimal-invasiven ästhetischen Eingriffen steigt von Jahr zu Jahr mit einer rasanten Geschwindigkeit. Neben Botulinumtoxin und Laserbehandlungen stellt die Unterspritzung mit Dermalfillern eine der wichtigsten Methoden dar. Dermalfiller können für zahlreiche Behandlungsindikationen eingesetzt werden: Falten (feine bis tiefe), Lippenaufbau, Gesichtsdeformitäten, eingesunkene Narben, HIV-assoziierte Lipoatrophie, an Händen, Hals und Dekolletee. Derzeit sind über 160 Dermalfiller im Handel. Sie unterscheiden sich stark in Ursprung (eigen- oder fremdhuman, tierisch, fermentativ oder synthetisch), Dauer des Effekts und Abbauverhalten (temporär, semipermanent, permanent), Injektionstiefe (dermal, subkutan, supraperiostal) sowie Risikoprofil. Ärzte, die Dermalfiller einsetzen, sollten eine genaue Kenntnis dieser Eigenschaften sowie der anatomischen Gegebenheiten im Behandlungsareal haben. Dies ist für den korrekten Einsatz und ein optimales ästhetisches Ergebnis essenziell. Vor jeder Behandlung sollten der Ablauf der Behandlung, gewünschte Effekte, Haltbarkeit und potenzielle Risiken des einzusetzenden Fillers mit dem Patienten diskutiert werden. Die Auswahl des Dermalfillers, die Injektionstechnik und das eingesetzte Volumen richten sich nach der anatomischen Lokalisation, der Art des Defekts, dem gewünschten Effekt und der Erfahrung des Arztes.

Abstract

The demand for minimally invasive cosmetic procedures is increasing rapidly every year. In addition to botulinum toxin and laser treatments, the injection of dermal fillers is one of the most relevant methods. Dermal fillers can be used for a multitude of indications: wrinkles (fine to deep), lip augmentation, facial deformities, sunken scars, and HIV-related lipoatrophy in hands, neck and décolleté. There are currently 160 dermal fillers on the market. They differ greatly in terms of origin (own or cadaveric-derived, animal, bacterial fermentation or synthesis), duration of the effect and breakdown properties (temporary, semi-permanent, permanent), injection depth (dermal, subcutaneous, supraperiosteal), and risk profile. Physicians who administer dermal fillers should have a thorough knowledge of their characteristics and of the anatomy of the area to be treated. This is essential for correct administration and optimal aesthetic results. Prior to any treatment, details of the procedure, the desired effects, durability, and potential risks of the filler to be injected should be discussed with the patient. The choice of dermal filler, the injection technique, and the volume to be administered are determined according to the anatomic site, the type of defect, the desired effect, and physician experience.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Baumann LS, Shamban AT, Lupo MP (2007) Comparison of smooth gel hyaluronic acid dermal fillers with crosslinked bovine collagen: a multicenter, double-masked, randomized, within-subject study. Dermatol Surg 33 (Suppl 2):128−135

    Article  CAS  Google Scholar 

  2. Beer K (2007) A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne orvaricella. Dermatol Surg 33 (Suppl. 2):159–167

    Google Scholar 

  3. Broder KW, Cohen SR (2006) An overview of permanent and semipermanent filler. Plast Reconstr Surg 118 (Suppl):7–15

    Article  CAS  Google Scholar 

  4. Buelow S von, Heimburg D von, Pallua N (2005) Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr Surg 116:1137–1146

    Article  CAS  Google Scholar 

  5. Butterwick KJ, Nootheti PK, Hsu JW, Goldman MP (2007) Autologous fat transfer: an in-depth look at varying concepts and techniques. Facial Plast Surg Clin North Am 15:99–111

    Article  PubMed  Google Scholar 

  6. Carruthers A, Carey W, De Lorenzi C et al (2005) A randomized, double-blind comparison of the efficacy of two hyaluronic acid derivates, restylane perlane and hylaform, in the treatment of nasolabial folds. Dermatol Surg 31:1591–1598

    PubMed  CAS  Google Scholar 

  7. Carruthers A, Carruthers J (2007) Non-animal-based hyaluronic acid fillers: scientific and technical considerations. Plast Reconstr Surg 120 (Suppl):33–40

    Article  CAS  Google Scholar 

  8. Christensen L, Breiting V, Janssen M (2005) Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 29:34–48

    Article  PubMed  Google Scholar 

  9. Cohen SR, Holmes RE (2004) Artecoll: a long-lasting injectable wrinkle filler material. Report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 114:964–976

    Article  PubMed  Google Scholar 

  10. Coleman SR (2006) Facial augmentation with structural fat grafting. Clin Plast Surg 33:567–577

    Article  PubMed  Google Scholar 

  11. Dijkema SJ, Lei B van der, Kibbelaar RE (2005) New-Fill injections may induce late-onset foreign body granulomatous reaction. Plasr Reconstr Surg 115:76–78

    Article  Google Scholar 

  12. Dirting K, Lampe H, Wolters M et al (2008) Hyaluronsäurefiller zur Korrektur der Nasolabialfalten – Ergebnisse einer klinischen Studie. JDDG 6 (Suppl 2):S10–S14

    Article  PubMed  Google Scholar 

  13. Dover JS, Carruthers A, Carruthers J, Alam M (2005) Clinical use of Restylane. Skin Ther Lett 10:5–7

    CAS  Google Scholar 

  14. Elson ML (1989) The role of skin testing in the use of collagen injectable materials. J Dermatol Surg Oncol 15:301–303

    PubMed  CAS  Google Scholar 

  15. Eppley BI, Dadvand B (2006) Injectable soft-tissue fillers: clinical overview. Plast Reconstr Surg 118:98–106

    Article  CAS  Google Scholar 

  16. Jacovella PF, Peiretti CB, Cunille DR (2006) Long lasting results with hydroxylapatite facial filler. Plast Reconstr Surg 118 (Suppl 3):15–21

    Article  CAS  Google Scholar 

  17. Lemperle G, Gauthier-Hazan N, Lemperle M (1998) PMMA-microspheres (Artecoll) for long-lasting correction of wrinkles: refinements and statistical results. Aesthetic Plast Surg 22:356–365

    Article  PubMed  CAS  Google Scholar 

  18. Lemperle G, Morhenn V, Charrier U (2003) Human histology and persistence of various injectable filler substances for soft tissue augnmentation. Aesthetic Plast Surg 27:354–366

    Article  PubMed  Google Scholar 

  19. Lupo MP, Smith SR, Thomas JA et al (2008) Effectiveness of Juvederm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 121:289–297

    Article  PubMed  CAS  Google Scholar 

  20. Mandeville JT, Rubin PA (2004) Injectable agents for facial rejuvenation: botulinumtoxin and dermal filling agents. Int Ophthalmol Clin 44:189–212

    Article  PubMed  Google Scholar 

  21. Marmur ES, Phelps R, Goldberg DJ (2004) Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 6:223–226

    Article  PubMed  Google Scholar 

  22. Monheit GD, Coleman KM (2006) Hyaluronic acid fillers. Dermatol Ther 19:141–150

    Article  PubMed  Google Scholar 

  23. Montgomery H (1987) In: Dermatopathology. Harper & Raw, New York, pp 403–415

  24. Morhenn VB, Lemperle G, Gallo RL (2002) Phagocytosis of different particulate dermal filler substances by human macrophages and skin cells. Dermatol Surg 28:484–490

    Article  PubMed  Google Scholar 

  25. Moyle GJ, Lysakova L, Brown S (2004) A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 5:82–87

    Article  PubMed  CAS  Google Scholar 

  26. Naoum C, Dasiou Plakida D (2001) Dermalfiller materials and botulinum toxin: review. Int J Dermatol 40:609–621

    Article  PubMed  CAS  Google Scholar 

  27. Narins RS, Bowman PH (2005) Injectable skin fillers. Clin Plast Surg 32:151–162

    Article  PubMed  Google Scholar 

  28. Narins RS, Brandt F, Leyden J et al (2003) A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for correction of nasolabial folds. Dermatol Surg 29:588–595

    Article  PubMed  Google Scholar 

  29. Narins RS, Brandt FS, Lorenc ZP et al (2008) Twelve months persistency of a novel ribose-cross-linked collagen dermal filler. Dermatol Surg 34 (Suppl 1):31–39

    Article  CAS  Google Scholar 

  30. Narins RS, Brandt FS, Lorenc ZP et al (2007) A randomized, multicenter study of the safety and efficacy of Dermicol-P35 and non-animal-stabilized hyaluronic acid gel for the correction of nasolabial folds. Dermatol Surg 33 (Suppl 2):213–221

    Article  CAS  Google Scholar 

  31. Neudecker BA, Csoka AB, Mio K (2000) Hyaluronan: the natural skin moisturizer. In: Elsner P, Maibach HI (eds) Cosmeceuticals: drugs vs. cosmetics, 1st edn. Marcel Dekker, New York, pp 319–355

  32. Radiesse Datasheet. Available at: http://www.bioformmedical.com

  33. Reinmüller J (2008) Hyaluronsäure in der ästhetischen Medizin – Historie, Entwicklung und heutige Bedeutung. JDDG 6 (Suppl 2):4–9

    Article  Google Scholar 

  34. Sherman RN (2006) Sculptra: the new three-dimensional filler. Clin Plast Surg 33:539–550

    Article  PubMed  Google Scholar 

  35. Shoshani D, Markovitz E, Cohen Y et al (2007) Skin test hypersensitivity study of a cross-linked, porcine collagen implant for aesthetic surgery. Dermatol Surg 33 (Suppl 2):152–158

    Article  CAS  Google Scholar 

  36. Testimony of the FDA Commissioner, Dr. D. Kess, before the House of Representatives Human Resources Intergovernmental Relations Subcommittee, June 11, 1991, regarding „Promoting Drugs for Unproved Uses“

  37. Tzikas Tl (2006) Autologous fat grafting for midface rejuvenation. Facial Plast Surg Clin North Am 118 (Suppl 1):108–120

    Google Scholar 

  38. Valantin MA, Aubron-Olivier C, Ghosn J (2003) Polylactic acid implants (new fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17:2471–2477

    Article  PubMed  CAS  Google Scholar 

  39. Vedamurthy M (2008) Standard guidelines for the use of dermal fillers. Indian J Dermatol Venereol Leprol (Suppl) 74:23–27

    Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität München, Frauenlobstraße 9–11, 80337, München, Deutschland

    T. Pavicic

Authors
  1. T. Pavicic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Pavicic.

Additional information

__ ____

Dieser Beitrag ist eine Aktualisierung von T. Pavicic, Filler – ein Überblick. J Ästhet Chir (2009) 2: 15–22; DOI s12631-008-0012-9.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pavicic, T. Dermatofiller. Hautarzt 60, 233–245 (2009). https://doi.org/10.1007/s00105-009-1723-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-009-1723-3

Schlüsselwörter

Keywords

Search

Navigation